Skip to main content
idi
Toggle navigation
0
You have 0 notifications
Site Visitor
Site Visitor
New To Inknowvation.com?
Register now to get an access to proprietary SBIR-STTR databases!
Registration is fast and free - start your access to business-actionable information today!
Login
Site Register
SBIR-STTR Award
You are here:
Home
Search Databases
Search SBIR-STTR Awards
SBIR-STTR Award
10
Sentinel Lymph Node Staging With Magnetic Nanoparticles
Award last edited on: 2/25/02
Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$98,706
Award Phase
1
Solicitation Topic Code
-----
Principal Investigator
Jerome W Lewis
Company Information
AMAG Pharmaceuticals Inc
(
AKA
: Advanced Magnetics Inc)
1100 Winter Street
Waltham, MA 02451
(617) 498-3300
contactus@amagpharma.com
www.amagpharma.com
Location:
Single
Congr. District:
05
County:
Middlesex
Phase I
Contract Number:
1R43CA083457-01
Start Date:
00/00/00
Completed:
00/00/00
Phase I year
1999
Phase I Amount
$98,706
The goal is to develop a noninvasive MRI technique using colloidal magnetite contrast agents for sentinel lymph node (SLN) mapping and staging with application to melanoma and breast cancer patients. Peritumoral injections of these magnetite nanoparticles would limit their distribution to the lymphatic drainage basin near the primary tumor. Application of this technique would lower medical costs by assuring that SLN location and assessment would involve less doctor-patient contact and decrease patient morbidity. Our specific goals are 1) develop new magnetite nanoparticles specifically for sentinel lymph node staging or mapping. These nanoparticles will exhibit minimal retention at the site of injection and move rapidly and efficiently to the SLN. 2) Determine the effect of nanoparticle surface properties on nodal nanoparticle uptake rates. 3) Determine the effect of massage and muscular movement on efficacy of nodal loading. 4) Determine the optimum dose and imaging protocols for SLN staging. The development of this technique will enable oncologists to locate sentinel lymph nodes in cancer patients and perhaps eliminate the need for elective lymphadenectomy or sentinel lymph node dissection. PROPOSED COMMERCIAL APPLICATIONS: The market for a MRI contrast agent designed for sentinel lymph node detection and staging in the US alone is large with a potential of >180000 breast cancer patients and approximately 38000 melanoma patients annually. This technique may also be applicable to other solid cancers with nodal metastases. The spread of the primary tumor to the regional lymph nodes is an important prognostic indicator for long term survival of cancer patients. Unfortunately, there is no reliable non-invasive technique for assessing lymph node status in cancer patients. Our technique may eliminate the need for surgical assessment of lymph node status
Phase II
Contract Number:
----------
Start Date:
00/00/00
Completed:
00/00/00
Phase II year
----
Phase II Amount
----
×
Login to your account
Mail sent successfully.
Enter any username and password.
Username
Password
Remember me
Login
Forgot your username?
Click here for assistance
Forgot your password?
Request new password
Don't have an account?
Sign up
Forgot username?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.
Forgot password?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.